NKT cell stimulation with α-galactosylceramide results in a block of Th17 differentiation after intranasal immunization in mice.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
AbstractIn a previous study we demonstrated that intranasal (i.n.) vaccination promotes a Th17 biased immune response. Here, we show that co-administration of a pegylated derivative of α-galactosylceramide (αGCPEG) with an antigen, even in the presence of Th17-polarizing compounds, results in a strong blocking of Th17 differentiation. Additional studies demonstrated that this phenomenon is specifically dependent on soluble factors, like IL-4 and IFNγ, which are produced by NKT cells. Even NK1.1 negative NKT cells, which by themselves produce IL-17A, are able to block Th17 differentiation. It follows that the use of αGCPEG as adjuvant would enable to tailor Th17 responses, according to the specific clinical needs. This knowledge expands our understanding of the role played by NKT cells in overall control of the cytokine microenvironment, as well as in the overall shaping of adaptive immune responses.
CitationNKT cell stimulation with α-galactosylceramide results in a block of Th17 differentiation after intranasal immunization in mice. 2012, 7 (1):e30382 PLoS ONE
AffiliationDepartment of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany. email@example.com
The following license files are associated with this item:
- Intranasal but not intravenous delivery of the adjuvant α-galactosylceramide permits repeated stimulation of natural killer T cells in the lung.
- Authors: Courtney AN, Thapa P, Singh S, Wishahy AM, Zhou D, Sastry J
- Issue date: 2011 Nov
- Invariant NKT cells regulate experimental autoimmune uveitis through inhibition of Th17 differentiation.
- Authors: Oh K, Byoun OJ, Ham DI, Kim YS, Lee DS
- Issue date: 2011 Feb
- Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy.
- Authors: Thapa P, Zhang G, Xia C, Gelbard A, Overwijk WW, Liu C, Hwu P, Chang DZ, Courtney A, Sastry JK, Wang PG, Li C, Zhou D
- Issue date: 2009 May 26
- Mechanism of NKT cell activation by intranasal coadministration of alpha-galactosylceramide, which can induce cross-protection against influenza viruses.
- Authors: Kamijuku H, Nagata Y, Jiang X, Ichinohe T, Tashiro T, Mori K, Taniguchi M, Hase K, Ohno H, Shimaoka T, Yonehara S, Odagiri T, Tashiro M, Sata T, Hasegawa H, Seino KI
- Issue date: 2008 May
- α-Galactosylceramide-induced airway eosinophilia is mediated through the activation of NKT cells.
- Authors: Chuang YH, Wang TC, Jen HY, Yu AL, Chiang BL
- Issue date: 2011 Apr 15